Brown A, et al. - Researchers performed this phase 2 C-SCAPE study to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with HCV genotype 2, 4, 5 or 6 infection. This was a part randomised, open-label, parallel-group study of treatment-naive, noncirrhotic participants. Findings provide support to the inclusion of participants with genotype 4 or 6 infection in the EBR/GZR phase 3 studies. For participants with genotype 2 or 5 infection, EBR/GZR ± RBV was unsatisfactory.